BiotechTube

Buntanetap/Posiphen + Placebo

Phase 2/3Completed
0 watching 0 views this week⚡ Active
57
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Alzheimer Disease

Conditions

Alzheimer Disease

Trial Timeline

Apr 1, 2023 → Feb 13, 2024

NCT ID
NCT05686044

About Buntanetap/Posiphen + Placebo

Buntanetap/Posiphen + Placebo is a phase 2/3 stage product being developed by Annovis Bio for Alzheimer Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT05686044. Target conditions include Alzheimer Disease.

Hype Score Breakdown

Clinical
22
Activity
15
Company
2
Novelty
7
Community
8

Clinical Trials (3)

NCT IDPhaseStatus
NCT06709014Phase 3Recruiting
NCT05686044Phase 2/3Completed
NCT05357989Phase 3Completed

Competing Products

20 competing products in Alzheimer Disease

See all competitors
ProductCompanyStageHype Score
[18F]NAV4694Navidea BiopharmaceuticalsPhase 2
44
Bromocriptine Mesilate + PlacebosTowa PharmaceuticalPhase 1/2
40
LY450139 + PlaceboEli LillyPhase 3
77
Solanezumab + PlaceboEli LillyPhase 3
77
LY450139 dihydrate + placeboEli LillyPhase 2
52
Zagotenemab + PlaceboEli LillyPhase 2
52
Donanemab + Placebo + LY3202626Eli LillyPhase 2
52
Donanemab + PlaceboEli LillyPhase 3
77
GSK4527226AlectorPhase 2
44
AL002 + PlaceboAlectorPhase 2
44
GSK4527226AlectorPhase 2
44
AL002AlectorPhase 2
44
Solanezumab + PlaceboEli LillyPhase 3
77
donanemabEli LillyPhase 2
52
ATH-1017LeonaBioPhase 2/3
57
ATH-1017 + PlaceboLeonaBioPhase 2/3
57
ATH-1017 + PlaceboLeonaBioPhase 2
44
NDX-1017 + PlaceboLeonaBioPhase 1
25
simufilamCassava SciencesPhase 2
44
50 mg PTI-125 + 100 mg PTI-125 + 200 mg PTI-125Cassava SciencesPhase 1
25

Other Products from Annovis Bio

buntanetap/posiphen + PlaceboPhase 3
69
buntanetap/posiphen + PlaceboPhase 3
69
buntanetap/posiphenPhase 2/3
57
Posiphen + PlaceboPhase 1/2
33
Posiphen + PlaceboPhase 1/2
33